Skip to main content
SpringerLink
Log in

Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study

  • Pharmacodynamics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Nonsteroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid (ASA) are often prescribed concurrently in patients with nociceptive pain and cardiovascular comorbidity. NSAIDs and ASA inhibit the same COX-enzymes, and thus may interact. ASA’s cardioprotective antiplatelet effect is entirely COX-1 dependent. NSAIDs can be either non-COX-1 and COX-2 selective or COX-2 selective. The aim of this study was to examine the interaction between ASA and different selective and nonselective NSAIDs on thrombocyte function.

Methods

Single-blind, prospective, placebo-controlled, ex vivo, serial crossover trial of 3-day cycles separated by washout periods of at least 12 days in 30 healthy volunteers, evaluating interaction on ASA’s antithrombocyte effect by naproxen, ibuprofen, meloxicam, or etoricoxib taken 2 h before ASA. Ex vivo thrombocyte function, closure time (CT) in seconds, was measured using the Platelet Function Analyzer 100 (PFA-100). CT prolongation during a cycle reflects thrombocyte inhibitory effect. ASA nonresponse was defined as CT prolongation <40 % in the placebo cycle. ASA nonresponders were excluded. Wilcoxon signed-rank was used to evaluate NSAID effect on ASA-induced CT prolongation.

Results

Ibuprofen and naproxen inhibit ASA’s antithrombocyte effect below the nonresponse threshold. Etoricoxib and meloxicam do not cause relevant change in ASA thrombocyte inhibition. Naproxen has an inherent weak thrombocyte inhibitory action below the ASA response threshold.

Conclusions

COX-1 affinity determines the interaction between NSAIDs and ASA on thrombocyte adhesion and aggregation. Ibuprofen and naproxen, but not etoricoxib or meloxicam, taken 2 h before ASA, significantly inhibit ASA’s antithrombocyte effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Al-Windi A (2005) Determinants of medicine use in a Swedish primary health care practice population. Pharmacoepidemiol Drug Saf 14(1):47–51

    Article  PubMed  Google Scholar 

  2. Nobili A, Franchi C, Pasina L et al (2011) Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-elderly project. Pharmacoepidemiol Drug Saf 20(5):488–496

    Article  PubMed  Google Scholar 

  3. Pilotto A, Franceschi M, Leandro G, Di Mario F (2003) NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging 20(9):701–710

    Article  PubMed  CAS  Google Scholar 

  4. Dorp V, Beerthuis RK, Nugteren DH, Vonkeman H (1964) The biosynthesis of prostaglandins. Biochim Biophys Acta 90:204–207

    Article  CAS  Google Scholar 

  5. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P (1990) The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265(28):16737–16740

    PubMed  CAS  Google Scholar 

  6. Van Hecken A, Schwartz JI, Depre M et al (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40(10):1109–1120

    PubMed  Google Scholar 

  7. Hawkey CJ (1999) COX-2 inhibitors. Lancet 353(9149):307–314

    Article  PubMed  CAS  Google Scholar 

  8. Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809–1817

    Article  PubMed  CAS  Google Scholar 

  9. Schuijt MP, Huntjens-Fleuren HW, de Metz M, Vollaard EJ (2009) The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol 157(6):931–934

    Article  PubMed  CAS  Google Scholar 

  10. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N (2008) The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101(7):1060–1063

    Article  PubMed  CAS  Google Scholar 

  11. Capone ML, Sciulli MG, Tacconelli S et al (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45(8):1295–1301

    Article  PubMed  CAS  Google Scholar 

  12. Anzellotti P, Capone ML, Jeyam A et al (2011) Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 63(3):850–859

    Article  PubMed  CAS  Google Scholar 

  13. Kurth T, Glynn RJ, Walker AM et al (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108(10):1191–1195

    Article  PubMed  CAS  Google Scholar 

  14. MacDonald TM, Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361(9357):573–574

    Article  PubMed  CAS  Google Scholar 

  15. Kimmel SE, Strom BL (2003) Giving aspirin and ibuprofen after myocardial infarction. BMJ 327(7427):1298–1299

    Article  PubMed  Google Scholar 

  16. Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM (2003) Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 327(7427):1322–1323

    Article  PubMed  Google Scholar 

  17. Patel TN, Goldberg KC (2004) Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med 164(8):852–856

    Article  PubMed  CAS  Google Scholar 

  18. Trelle S, Reichenbach S, Wandel S et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342:c7086

    Article  PubMed  Google Scholar 

  19. Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and Knee. Arthritis Care Res 64(4):455–474

    Article  Google Scholar 

  20. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, American Heart Association (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115(12):1634–1642

    Article  PubMed  Google Scholar 

  21. Rodriguez TAG, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52(20):1628–1636

    Article  CAS  Google Scholar 

  22. Buerke M, Pittroff W, Meyer J, Darius H (1995) Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 130(3):465–472

    Article  PubMed  CAS  Google Scholar 

  23. Poulsen TS, Mickley H, Korsholm L, Licht PB, Haghfelt T, Jorgensen B (2007) Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. Thromb Res 120(2):161–172

    Article  PubMed  CAS  Google Scholar 

  24. Vonkeman HE, Van de Laar MA (2010) Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 39(4):294–312

    Article  PubMed  CAS  Google Scholar 

  25. Catella-Lawson F, Crofford LJ (2001) Cyclooxygenase inhibition and thrombogenicity. Am J Med 110(Suppl 3A):28S–32S

    Article  PubMed  CAS  Google Scholar 

  26. de Gaetano G, Cerletti C, Dejana E, Latini R (1985) Pharmacology of platelet inhibition in humans: implications of the salicilate-aspirin interaction. Circulation 72:1185–1193

    Article  PubMed  Google Scholar 

  27. Awa K, Satoh H, Hor S, Sawada Y (2012) Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. J Clin Pharm Ther 37:469–474

    Article  PubMed  CAS  Google Scholar 

  28. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG (2007) A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28(14):1702–1708

    Article  PubMed  CAS  Google Scholar 

  29. Favaloro EJ (2002) Clinical application of the PFA-100. Curr Opin Hematol 9(5):407–415

    Article  PubMed  Google Scholar 

  30. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, De Gaetano G (2008) Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 99(1):14–26

    PubMed  CAS  Google Scholar 

  31. Andersen K, Hurlen M, Arnesen H, Seljeflot I (2002) Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108(1):37–42

    Article  PubMed  Google Scholar 

  32. Poulsen TS, Jorgensen B, Korsholm L, Bjorn LP, Haghfelt T, Mickley H (2007) Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res 119(5):555–562

    Article  PubMed  CAS  Google Scholar 

  33. Gurbel PA, Tantry US (2007) Clopidogrel resistance? Thromb Res 120(3):311–321

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

None

Author information

Authors and Affiliations

  1. Arthritis Center Twente, University Twente and Medisch Spectrum Twente, 7500KA, Enschede, Netherlands

    I. L. Meek, H. E. Vonkeman, J. Kasemier, K. L. L. Movig & M. A. F. J. van de Laar

Authors
  1. I. L. Meek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. E. Vonkeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Kasemier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. L. L. Movig
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. A. F. J. van de Laar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. L. Meek.

Additional information

Clinical Trial Registration: Protocol ID APOMST003, EudraCT nr 2008-008954-22

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 665 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meek, I.L., Vonkeman, H.E., Kasemier, J. et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol 69, 365–371 (2013). https://doi.org/10.1007/s00228-012-1370-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-012-1370-y

Keywords

Search

Navigation